{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T01:39:57Z","timestamp":1794879597201,"version":"4.9.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["CREST"],"award-info":[{"award-number":["CREST"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["18H02744"],"award-info":[{"award-number":["18H02744"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["18KT0027"],"award-info":[{"award-number":["18KT0027"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["18KK0242"],"award-info":[{"award-number":["18KK0242"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Although various body fluid biomarkers for amyotrophic lateral sclerosis (ALS) have been reported, no biomarkers specifically reflecting abnormalities in axonal excitability indices have currently been established. Capillary electrophoresis time-of-flight mass spectrometry and liquid chromatography time-of-flight mass spectrometry were used to perform a comprehensive metabolome analysis of plasma from seven ALS patients and 20 controls, and correlation analysis with disease phenotypes was then performed in 22 other ALS patients. Additionally, electrophysiological studies of motor nerve axonal excitability were performed in all ALS patients. In the ALS and control groups, levels of various metabolites directly associated with skeletal muscle metabolism, such as those involved in fatty acid \u03b2-oxidation and the creatine pathway, were detected. Receiver operating characteristic curve analysis of the top four metabolites (ribose-5-phosphate, N6-acetyllysine, dyphylline, 3-methoxytyrosine) showed high diagnostic accuracy (area under the curve\u2009=\u20090.971) in the ALS group compared with the control group. Furthermore, hierarchical cluster analysis revealed that taurine levels were correlated with the strength-duration time constant, an axonal excitability indicator established to predict survival. No significant effects of diabetes mellitus and treatment (Riluzole and Edaravone) on this relationship were detected in the study. Therefore, plasma taurine is a potential novel axonal excitability-translatable biomarker for ALS.<\/jats:p>","DOI":"10.1038\/s41598-022-13397-6","type":"journal-article","created":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T17:06:12Z","timestamp":1654103172000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Plasma taurine is an axonal excitability-translatable biomarker for amyotrophic lateral sclerosis"],"prefix":"10.1038","volume":"12","author":[{"given":"Tomoko","family":"Nakazato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Kanai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsushi","family":"Kataura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuko","family":"Nojiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobutaka","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Saiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,1]]},"reference":[{"key":"13397_CR1","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1080\/146608200300079536","volume":"1","author":"BR Brooks","year":"2000","unstructured":"Brooks, B. R., Miller, R. G., Swash, M., Munsat, T. L., World Federation of Neurology Research Group on Motor Neuron, D. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 1, 293\u2013299 (2000).","journal-title":"Amyotroph. Lateral Scler. Other Motor Neuron Disord."},{"key":"13397_CR2","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.clinph.2007.09.143","volume":"119","author":"M de Carvalho","year":"2008","unstructured":"de Carvalho, M. et al. Electrodiagnostic criteria for diagnosis of ALS. Clin. Neurophysiol. 119, 497\u2013503. https:\/\/doi.org\/10.1016\/j.clinph.2007.09.143 (2008).","journal-title":"Clin. Neurophysiol."},{"key":"13397_CR3","doi-asserted-by":"publisher","first-page":"310","DOI":"10.3109\/17482960802566824","volume":"10","author":"A Chio","year":"2009","unstructured":"Chio, A. et al. Prognostic factors in ALS: A critical review. Amyotroph. Lateral Scler. 10, 310\u2013323. https:\/\/doi.org\/10.3109\/17482960802566824 (2009).","journal-title":"Amyotroph. Lateral Scler."},{"key":"13397_CR4","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1002\/(SICI)1097-4598(199803)21:3<336::AID-MUS7>3.0.CO;2-B","volume":"21","author":"M de Carvalho","year":"1998","unstructured":"de Carvalho, M. & Swash, M. Fasciculation potentials: A study of amyotrophic lateral sclerosis and other neurogenic disorders. Muscle Nerve 21, 336\u2013344 (1998).","journal-title":"Muscle Nerve"},{"key":"13397_CR5","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1212\/01.wnl.0000194316.91908.8a","volume":"66","author":"F Kimura","year":"2006","unstructured":"Kimura, F. et al. Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology 66, 265\u2013267. https:\/\/doi.org\/10.1212\/01.wnl.0000194316.91908.8a (2006).","journal-title":"Neurology"},{"key":"13397_CR6","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1136\/jnnp-2011-300141","volume":"82","author":"C Fujimura-Kiyono","year":"2011","unstructured":"Fujimura-Kiyono, C. et al. Onset and spreading patterns of lower motor neuron involvements predict survival in sporadic amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry 82, 1244\u20131249. https:\/\/doi.org\/10.1136\/jnnp-2011-300141 (2011).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"13397_CR7","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1136\/jnnp-2011-301782","volume":"83","author":"K Kanai","year":"2012","unstructured":"Kanai, K. et al. Motor axonal excitability properties are strong predictors for survival in amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry 83, 734\u2013738. https:\/\/doi.org\/10.1136\/jnnp-2011-301782 (2012).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"13397_CR8","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1002\/acn3.51194","volume":"7","author":"QJ Zhang","year":"2020","unstructured":"Zhang, Q. J. et al. Promoting identification of amyotrophic lateral sclerosis based on label-free plasma spectroscopy. Ann. Clin. Transl. Neurol. 7, 2010\u20132018. https:\/\/doi.org\/10.1002\/acn3.51194 (2020).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"13397_CR9","doi-asserted-by":"publisher","first-page":"e404","DOI":"10.1212\/WNL.0000000000004888","volume":"90","author":"M Fujimaki","year":"2018","unstructured":"Fujimaki, M. et al. Serum caffeine and metabolites are reliable biomarkers of early Parkinson disease. Neurology 90, e404\u2013e411. https:\/\/doi.org\/10.1212\/WNL.0000000000004888 (2018).","journal-title":"Neurology"},{"key":"13397_CR10","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/S1474-4422(16)00070-3","volume":"15","author":"B Olsson","year":"2016","unstructured":"Olsson, B. et al. CSF and blood biomarkers for the diagnosis of Alzheimer\u2019s disease: A systematic review and meta-analysis. Lancet Neurol. 15, 673\u2013684. https:\/\/doi.org\/10.1016\/S1474-4422(16)00070-3 (2016).","journal-title":"Lancet Neurol."},{"key":"13397_CR11","doi-asserted-by":"publisher","first-page":"7328","DOI":"10.1038\/s41598-017-06767-y","volume":"7","author":"S Saiki","year":"2017","unstructured":"Saiki, S. et al. Decreased long-chain acylcarnitines from insufficient beta-oxidation as potential early diagnostic markers for Parkinson\u2019s disease. Sci. Rep. 7, 7328. https:\/\/doi.org\/10.1038\/s41598-017-06767-y (2017).","journal-title":"Sci. Rep."},{"key":"13397_CR12","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1002\/ana.25516","volume":"86","author":"S Saiki","year":"2019","unstructured":"Saiki, S. et al. A metabolic profile of polyamines in parkinson disease: A promising biomarker. Ann. Neurol. 86, 251\u2013263. https:\/\/doi.org\/10.1002\/ana.25516 (2019).","journal-title":"Ann. Neurol."},{"key":"13397_CR13","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1002\/mds.28068","volume":"35","author":"H Takeshige-Amano","year":"2020","unstructured":"Takeshige-Amano, H. et al. Shared metabolic profile of caffeine in parkinsonian disorders. Mov. Disord. 35, 1438\u20131447. https:\/\/doi.org\/10.1002\/mds.28068 (2020).","journal-title":"Mov. Disord."},{"key":"13397_CR14","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/ene.12956","volume":"23","author":"H Blasco","year":"2016","unstructured":"Blasco, H. et al. Metabolomics in amyotrophic lateral sclerosis: how far can it take us?. Eur. J. Neurol. 23, 447\u2013454. https:\/\/doi.org\/10.1111\/ene.12956 (2016).","journal-title":"Eur. J. Neurol."},{"key":"13397_CR15","doi-asserted-by":"publisher","first-page":"611","DOI":"10.3389\/fnins.2016.00611","volume":"10","author":"TW Tefera","year":"2016","unstructured":"Tefera, T. W. & Borges, K. Metabolic dysfunctions in amyotrophic lateral sclerosis pathogenesis and potential metabolic treatments. Front. Neurosci. 10, 611. https:\/\/doi.org\/10.3389\/fnins.2016.00611 (2016).","journal-title":"Front. Neurosci."},{"key":"13397_CR16","doi-asserted-by":"publisher","first-page":"3276","DOI":"10.1021\/acs.jproteome.0c00216","volume":"19","author":"MS Bereman","year":"2020","unstructured":"Bereman, M. S. et al. Metabolite profiling reveals predictive biomarkers and the absence of beta-methyl amino-l-alanine in plasma from individuals diagnosed with amyotrophic lateral sclerosis. J. Proteome Res. 19, 3276\u20133285. https:\/\/doi.org\/10.1021\/acs.jproteome.0c00216 (2020).","journal-title":"J. Proteome Res."},{"key":"13397_CR17","first-page":"667","volume-title":"Lehninger Principles of Biochemistry","author":"DL Nelson","year":"2017","unstructured":"Nelson, D. L., Cox, M. M. & Lehninger, A. L. Lehninger Principles of Biochemistry 7th edn, 667\u2013693 (W.H. Freeman and Company, 2017).","edition":"7"},{"key":"13397_CR18","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1080\/21678421.2019.1572192","volume":"20","author":"D Lanznaster","year":"2019","unstructured":"Lanznaster, D. et al. Plasma creatinine and amyotrophic lateral sclerosis prognosis: A systematic review and meta-analysis. Amyotroph. Lateral Scler. Frontotemporal Degener 20, 199\u2013206. https:\/\/doi.org\/10.1080\/21678421.2019.1572192 (2019).","journal-title":"Amyotroph. Lateral Scler. Frontotemporal Degener"},{"key":"13397_CR19","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1080\/21678421.2020.1746810","volume":"21","author":"H Mitsumoto","year":"2020","unstructured":"Mitsumoto, H. et al. Plasma creatinine and oxidative stress biomarkers in amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Frontotemporal Degener. 21, 263\u2013272. https:\/\/doi.org\/10.1080\/21678421.2020.1746810 (2020).","journal-title":"Amyotroph. Lateral Scler. Frontotemporal Degener."},{"key":"13397_CR20","first-page":"1336","volume-title":"Adams and Victor's Principles of Neurology","author":"AH Ropper","year":"2019","unstructured":"Ropper, A. H., Samuels, M. A. & Klein, J. Adams and Victor\u2019s Principles of Neurology 11th edn, 1336\u20131339 (McGraw-Hill Education, 2019).","edition":"11"},{"key":"13397_CR21","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1093\/brain\/awh476","volume":"128","author":"AV Krishnan","year":"2005","unstructured":"Krishnan, A. V. & Kiernan, M. C. Altered nerve excitability properties in established diabetic neuropathy. Brain 128, 1178\u20131187. https:\/\/doi.org\/10.1093\/brain\/awh476 (2005).","journal-title":"Brain"},{"key":"13397_CR22","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.clinph.2004.08.003","volume":"116","author":"S Misawa","year":"2005","unstructured":"Misawa, S., Kuwabara, S., Ogawara, K., Kitano, Y. & Hattori, T. Strength-duration properties and glycemic control in human diabetic motor nerves. Clin. Neurophysiol. 116, 254\u2013258. https:\/\/doi.org\/10.1016\/j.clinph.2004.08.003 (2005).","journal-title":"Clin. Neurophysiol."},{"key":"13397_CR23","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.diabres.2016.04.058","volume":"118","author":"G Akca","year":"2016","unstructured":"Akca, G., Yerdelen, D., Balci, M. K. & Uysal, H. The effects of hyperventilation on axonal excitability parameters in patients with diabetes mellitus and polyneuropathy. Diabetes Res. Clin. Pract. 118, 112\u2013120. https:\/\/doi.org\/10.1016\/j.diabres.2016.04.058 (2016).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"13397_CR24","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1002\/mus.26303","volume":"59","author":"P Gencpinar","year":"2019","unstructured":"Gencpinar, P., Celmeli, G., Duman, O., Haspolat, S. & Uysal, H. Tibial nerve axonal excitability in type 1 diabetes mellitus. Muscle Nerve 59, 76\u201381. https:\/\/doi.org\/10.1002\/mus.26303 (2019).","journal-title":"Muscle Nerve"},{"key":"13397_CR25","first-page":"526","volume-title":"Lehninger Principles of Biochemistry","author":"DL Nelson","year":"2017","unstructured":"Nelson, D. L., Cox, M. M. & Lehninger, A. L. Lehninger Principles of Biochemistry 7th edn, 526\u2013527 (W.H. Freeman and Company, 2017).","edition":"7"},{"key":"13397_CR26","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1136\/jnnp-2017-317077","volume":"89","author":"RPA van Eijk","year":"2018","unstructured":"van Eijk, R. P. A. et al. Monitoring disease progression with plasma creatinine in amyotrophic lateral sclerosis clinical trials. J. Neurol. Neurosurg. Psychiatry 89, 156\u2013161. https:\/\/doi.org\/10.1136\/jnnp-2017-317077 (2018).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"13397_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0017947","volume":"6","author":"A Wuolikainen","year":"2011","unstructured":"Wuolikainen, A., Moritz, T., Marklund, S. L., Antti, H. & Andersen, P. M. Disease-related changes in the cerebrospinal fluid metabolome in amyotrophic lateral sclerosis detected by GC\/TOFMS. PLoS ONE 6, e17947. https:\/\/doi.org\/10.1371\/journal.pone.0017947 (2011).","journal-title":"PLoS ONE"},{"key":"13397_CR28","doi-asserted-by":"publisher","first-page":"362","DOI":"10.3109\/21678421.2014.908311","volume":"15","author":"KA Lawton","year":"2014","unstructured":"Lawton, K. A. et al. Plasma metabolomic biomarker panel to distinguish patients with amyotrophic lateral sclerosis from disease mimics. Amyotroph. Lateral Scler. Frontotemporal Degener. 15, 362\u2013370. https:\/\/doi.org\/10.3109\/21678421.2014.908311 (2014).","journal-title":"Amyotroph. Lateral Scler. Frontotemporal Degener."},{"key":"13397_CR29","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S1474-4422(10)70224-6","volume":"10","author":"L Dupuis","year":"2011","unstructured":"Dupuis, L., Pradat, P. F., Ludolph, A. C. & Loeffler, J. P. Energy metabolism in amyotrophic lateral sclerosis. Lancet Neurol. 10, 75\u201382. https:\/\/doi.org\/10.1016\/S1474-4422(10)70224-6 (2011).","journal-title":"Lancet Neurol."},{"key":"13397_CR30","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s00401-018-1835-x","volume":"135","author":"T Vandoorne","year":"2018","unstructured":"Vandoorne, T., De Bock, K. & Van Den Bosch, L. Energy metabolism in ALS: An underappreciated opportunity?. Acta Neuropathol. 135, 489\u2013509. https:\/\/doi.org\/10.1007\/s00401-018-1835-x (2018).","journal-title":"Acta Neuropathol."},{"key":"13397_CR31","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1079\/9781780642000.0157","volume-title":"Metabolomics and Systems Biology in Human Health and Medicine","author":"J Shearer","year":"2014","unstructured":"Shearer, J. & Weljie, A. M. In Metabolomics and Systems Biology in Human Health and Medicine (ed. Jones, O. A. H.) 157\u2013170 (CABI, 2014)."},{"key":"13397_CR32","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/(SICI)1097-4598(199802)21:2<137::AID-MUS1>3.0.CO;2-C","volume":"21","author":"H Bostock","year":"1998","unstructured":"Bostock, H., Cikurel, K. & Burke, D. Threshold tracking techniques in the study of human peripheral nerve. Muscle Nerve 21, 137\u2013158 (1998).","journal-title":"Muscle Nerve"},{"key":"13397_CR33","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1002\/jnr.10027","volume":"66","author":"WQ Chen","year":"2001","unstructured":"Chen, W. Q. et al. Role of taurine in regulation of intracellular calcium level and neuroprotective function in cultured neurons. J. Neurosci. Res. 66, 612\u2013619. https:\/\/doi.org\/10.1002\/jnr.10027 (2001).","journal-title":"J. Neurosci. Res."},{"key":"13397_CR34","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1186\/1423-0127-17-S1-S1","volume":"17","author":"JY Wu","year":"2010","unstructured":"Wu, J. Y. & Prentice, H. Role of taurine in the central nervous system. J. Biomed. Sci. 17, S1. https:\/\/doi.org\/10.1186\/1423-0127-17-S1-S1 (2010).","journal-title":"J. Biomed. Sci."},{"key":"13397_CR35","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/978-1-4614-6130-2_2","volume":"775","author":"N Kumari","year":"2013","unstructured":"Kumari, N., Prentice, H. & Wu, J. Y. Taurine and its neuroprotective role. Adv. Exp. Med. Biol. 775, 19\u201327. https:\/\/doi.org\/10.1007\/978-1-4614-6130-2_2 (2013).","journal-title":"Adv. Exp. Med. Biol."},{"key":"13397_CR36","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/BF01920627","volume":"35","author":"Y Yoshino","year":"1979","unstructured":"Yoshino, Y., Koike, H. & Akai, K. Free amino acids in motor cortex of amyotrophic lateral sclerosis. Experientia 35, 219\u2013220 (1979).","journal-title":"Experientia"},{"key":"13397_CR37","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1136\/jnnp.54.11.984","volume":"54","author":"S Malessa","year":"1991","unstructured":"Malessa, S., Leigh, P. N., Bertel, O., Sluga, E. & Hornykiewicz, O. Amyotrophic lateral sclerosis: Glutamate dehydrogenase and transmitter amino acids in the spinal cord. J. Neurol. Neurosurg. Psychiatry 54, 984\u2013988 (1991).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"13397_CR38","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1523\/JNEUROSCI.16-01-00092.1996","volume":"16","author":"M Galarreta","year":"1996","unstructured":"Galarreta, M., Bustamante, J., Martin del Rio, R. & Solis, J. M. Taurine induces a long-lasting increase of synaptic efficacy and axon excitability in the hippocampus. J. Neurosci. 16, 92\u2013102 (1996).","journal-title":"J. Neurosci."},{"key":"13397_CR39","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1089\/neu.2019.6604","volume":"37","author":"D Sobrido-Camean","year":"2020","unstructured":"Sobrido-Camean, D. et al. Taurine promotes axonal regeneration after a complete spinal cord injury in lampreys. J. Neurotrauma 37, 899\u2013903. https:\/\/doi.org\/10.1089\/neu.2019.6604 (2020).","journal-title":"J. Neurotrauma"},{"issue":"Pt 5","key":"13397_CR40","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1093\/brain\/121.5.851","volume":"121","author":"I Mogyoros","year":"1998","unstructured":"Mogyoros, I., Kiernan, M. C., Burke, D. & Bostock, H. Strength-duration properties of sensory and motor axons in amyotrophic lateral sclerosis. Brain 121(Pt 5), 851\u2013859. https:\/\/doi.org\/10.1093\/brain\/121.5.851 (1998).","journal-title":"Brain"},{"issue":"Pt 1","key":"13397_CR41","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1093\/brain\/118.1.217","volume":"118","author":"H Bostock","year":"1995","unstructured":"Bostock, H., Sharief, M. K., Reid, G. & Murray, N. M. Axonal ion channel dysfunction in amyotrophic lateral sclerosis. Brain 118(Pt 1), 217\u2013225. https:\/\/doi.org\/10.1093\/brain\/118.1.217 (1995).","journal-title":"Brain"},{"key":"13397_CR42","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1016\/j.clinph.2006.04.016","volume":"117","author":"S Vucic","year":"2006","unstructured":"Vucic, S. & Kiernan, M. C. Axonal excitability properties in amyotrophic lateral sclerosis. Clin. Neurophysiol. 117, 1458\u20131466. https:\/\/doi.org\/10.1016\/j.clinph.2006.04.016 (2006).","journal-title":"Clin. Neurophysiol."},{"key":"13397_CR43","doi-asserted-by":"publisher","DOI":"10.3390\/cells8121471","author":"M Kusaczuk","year":"2019","unstructured":"Kusaczuk, M. Tauroursodeoxycholate-bile acid with chaperoning activity: Molecular and cellular effects and therapeutic perspectives. Cells https:\/\/doi.org\/10.3390\/cells8121471 (2019).","journal-title":"Cells"},{"key":"13397_CR44","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1056\/NEJMoa1916945","volume":"383","author":"S Paganoni","year":"2020","unstructured":"Paganoni, S. et al. Trial of sodium phenylbutyrate-taurursodiol for amyotrophic lateral sclerosis. N. Engl. J. Med. 383, 919\u2013930. https:\/\/doi.org\/10.1056\/NEJMoa1916945 (2020).","journal-title":"N. Engl. J. Med."},{"key":"13397_CR45","doi-asserted-by":"publisher","first-page":"5179","DOI":"10.1021\/acs.analchem.6b00188","volume":"88","author":"BJ Blaise","year":"2016","unstructured":"Blaise, B. J. et al. Power analysis and sample size determination in metabolic phenotyping. Anal. Chem. 88, 5179\u20135188. https:\/\/doi.org\/10.1021\/acs.analchem.6b00188 (2016).","journal-title":"Anal. Chem."},{"key":"13397_CR46","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/s13311-016-0492-9","volume":"14","author":"SB Park","year":"2017","unstructured":"Park, S. B., Kiernan, M. C. & Vucic, S. Axonal excitability in amyotrophic lateral sclerosis: Axonal excitability in ALS. Neurotherapeutics 14, 78\u201390. https:\/\/doi.org\/10.1007\/s13311-016-0492-9 (2017).","journal-title":"Neurotherapeutics"},{"key":"13397_CR47","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1001\/jamaneurol.2014.2940","volume":"72","author":"N Geevasinga","year":"2015","unstructured":"Geevasinga, N. et al. Axonal ion channel dysfunction in c9orf72 familial amyotrophic lateral sclerosis. JAMA Neurol. 72, 49\u201357. https:\/\/doi.org\/10.1001\/jamaneurol.2014.2940 (2015).","journal-title":"JAMA Neurol."},{"key":"13397_CR48","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2022857118","author":"T Teruya","year":"2021","unstructured":"Teruya, T., Chen, Y. J., Kondoh, H., Fukuji, Y. & Yanagida, M. Whole-blood metabolomics of dementia patients reveal classes of disease-linked metabolites. Proc. Natl. Acad. Sci. U.S.A. https:\/\/doi.org\/10.1073\/pnas.2022857118 (2021).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"13397_CR49","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1161\/CIRCRESAHA.117.311002","volume":"122","author":"RW McGarrah","year":"2018","unstructured":"McGarrah, R. W., Crown, S. B., Zhang, G. F., Shah, S. H. & Newgard, C. B. Cardiovascular metabolomics. Circ. Res. 122, 1238\u20131258. https:\/\/doi.org\/10.1161\/CIRCRESAHA.117.311002 (2018).","journal-title":"Circ. Res."},{"key":"13397_CR50","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1161\/CIRCRESAHA.120.315898","volume":"126","author":"ZZ Chen","year":"2020","unstructured":"Chen, Z. Z. & Gerszten, R. E. Metabolomics and proteomics in type 2 diabetes. Circ. Res. 126, 1613\u20131627. https:\/\/doi.org\/10.1161\/CIRCRESAHA.120.315898 (2020).","journal-title":"Circ. Res."},{"key":"13397_CR51","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/bs.acc.2018.02.002","volume":"85","author":"A Au","year":"2018","unstructured":"Au, A. Metabolomics and lipidomics of ischemic stroke. Adv. Clin. Chem. 85, 31\u201369. https:\/\/doi.org\/10.1016\/bs.acc.2018.02.002 (2018).","journal-title":"Adv. Clin. Chem."},{"key":"13397_CR52","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1039\/b714176a","volume":"4","author":"Y Ohashi","year":"2008","unstructured":"Ohashi, Y. et al. Depiction of metabolome changes in histidine-starved Escherichia coli by CE-TOFMS. Mol. Biosyst. 4, 135\u2013147. https:\/\/doi.org\/10.1039\/b714176a (2008).","journal-title":"Mol. Biosyst."},{"key":"13397_CR53","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1039\/c0mb00141d","volume":"7","author":"T Ooga","year":"2011","unstructured":"Ooga, T. et al. Metabolomic anatomy of an animal model revealing homeostatic imbalances in dyslipidaemia. Mol. Biosyst. 7, 1217\u20131223. https:\/\/doi.org\/10.1039\/c0mb00141d (2011).","journal-title":"Mol. Biosyst."},{"key":"13397_CR54","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/s11306-009-0178-y","volume":"6","author":"M Sugimoto","year":"2010","unstructured":"Sugimoto, M., Wong, D. T., Hirayama, A., Soga, T. & Tomita, M. Capillary electrophoresis mass spectrometry-based saliva metabolomics identified oral, breast and pancreatic cancer-specific profiles. Metabolomics 6, 78\u201395. https:\/\/doi.org\/10.1007\/s11306-009-0178-y (2010).","journal-title":"Metabolomics"},{"key":"13397_CR55","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/1471-2105-7-109","volume":"7","author":"BH Junker","year":"2006","unstructured":"Junker, B. H., Klukas, C. & Schreiber, F. VANTED: A system for advanced data analysis and visualization in the context of biological networks. BMC Bioinform. 7, 109. https:\/\/doi.org\/10.1186\/1471-2105-7-109 (2006).","journal-title":"BMC Bioinform."},{"key":"13397_CR56","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/(SICI)1097-4598(200003)23:3<399::AID-MUS12>3.0.CO;2-G","volume":"23","author":"MC Kiernan","year":"2000","unstructured":"Kiernan, M. C., Burke, D., Andersen, K. V. & Bostock, H. Multiple measures of axonal excitability: A new approach in clinical testing. Muscle Nerve 23, 399\u2013409 (2000).","journal-title":"Muscle Nerve"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-13397-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-13397-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-13397-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T04:05:30Z","timestamp":1669349130000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-13397-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,1]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["13397"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-13397-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,1]]},"assertion":[{"value":"10 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests<b>.<\/b>","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9155"}}